Michael Robinson joined Fox Business’ Stuart Varney on Tuesday to give viewers a preview of the 2015 tech market. Michael makes the bullish case for Gilead Sciences (Nasdaq: GILD). With more than 170 million people worldwide affected by hepatitis C, Gilead’s two “blockbuster” treatments promise to carry their revenues way beyond the current $8 billion level.
And Michael has some good things to say about SanDisk (Nasdaq: SNDK). This Silicon Valley flash memory leader – and major Apple Inc. (Nasdaq: AAPL) supplier – is about to reap the fruits of a powerful market catalyst. It’s a new storage device that’s certain to capture the youth market in 2015.